Patent search ap:("SOLVAY PHARM BV") AND inv:"VAN DER HEIJDEN JOHANNES A M" Page 1

1.

发明申请
AMPA ANTAGONIST FOR THE TREATMENT OF DIZZINESS, INCLUDING VERTIGO AND MENIERE'S DISORDER 审中-公开
Title translation: 用于治疗眩晕的AMPA拮抗剂，包括VERTIGO和MENIERE'S DISORDER

公开(公告)号：WO2006075020A3

公开(公告)日：2007-03-08

申请号：PCT/EP2006050194

申请日：2006-01-13

Applicant: SOLVAY PHARM BV , TURSKI LECHOSLAW A , VAN VLIET BERNARD J , REMIE RENE , VAN DER HEIJDEN JOHANNES A M , TULP MARTINUS TH M

Inventor： TURSKI LECHOSLAW A , VAN VLIET BERNARD J , REMIE RENE , VAN DER HEIJDEN JOHANNES A M , TULP MARTINUS TH M

IPC: A61K31/5517 , A61P27/16 , A61P43/00

CPC classification number: A61K31/551

Abstract: The invention relates to the use of 8,9-dimethyl-5-phenyl-11 H-1 ,3-dioxolo[4,5-h]-imidazo[1 ,2-c][2,3]benzodiazepine: tautomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of this compound and its tautomers and N-oxides, for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of dizziness, including vertigo and Meniere's disorder.

Abstract translation: 本发明涉及8,9-二甲基-5-苯基-11H-1,3-二氧杂环戊烯并[4,5-h] - 咪唑并[1,2-c] [2,3]苯并二氮杂：互变异构体和 N-氧化物，以及该化合物及其互变异构体和N-氧化物的药理学上可接受的盐，水合物和溶剂化物，用于制备用于治疗，改善或预防头晕的药物组合物，包括眩晕和美尼尔氏病。

2.

发明申请
METHOD OF TREATING PSYCHOTIC DISORDERS 审中-公开
Title translation: 治疗心理障碍的方法

公开(公告)号：WO0069424A2

公开(公告)日：2000-11-23

申请号：PCT/EP0003506

申请日：2000-04-14

Applicant: SOLVAY PHARM BV , HES ROELOF VAN , HEIJDEN JOHANNES A M V D , KRUSE CORNELIS G , LONG STEPHEN K

Inventor： VAN HES ROELOF , VAN DER HEIJDEN JOHANNES A M , KRUSE CORNELIS G , LONG STEPHEN K

IPC: C07D401/14 , A61K31/00 , A61K31/404 , A61K31/4184 , A61K31/4439 , A61K31/4523 , A61K31/517 , A61K31/519 , A61K45/06 , A61P25/18 , A61P43/00 , C07D209/14 , C07D209/46 , C07D209/48 , C07D403/08 , C07D513/04

CPC classification number: A61K31/4439 , A61K31/00

Abstract: The invention relates to the use of compounds having both dopamine D2-antagonistic activity and serotonin reuptake inhibitory (SRI) activity for the treatment of psychotic disorders such as schizophrenia. The invention further relates to a group of novel (1, 2, 3,6-tetrahydropyridin-4-yl) indole and -furan derivatives having these activities.

Abstract translation: 本发明涉及具有多巴胺D2拮抗活性和5-羟色胺再摄取抑制（SRI）活性的化合物用于治疗精神病性疾病如精神分裂症的用途。本发明还涉及一组具有这些活性的新的（1,2,3,6,6-四氢吡啶-4-基）吲哚和呋喃衍生物。

3.

发明专利
NEW PIPERAZINE AND PIPERIDINE COMPOUNDS 未知

公开(公告)号：CA2405971C

公开(公告)日：2010-03-30

申请号：CA2405971

申请日：2001-05-10

Applicant: SOLVAY PHARM BV

Inventor： FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , KRUSE CORNELIS G , LONG STEPHEN K , VAN SCHARRENBURG GUSTAAF J M

IPC: C07D413/10 , C07D413/14 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/445 , A61K31/4523 , A61K31/496 , A61P25/00 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/30 , A61P43/00 , C07D263/54 , C07D263/58 , C07D277/62 , C07D413/04 , C07D413/12

Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of the formula wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, ---Z represents -C, = C or -N, R1 and R2 independently represent hydrogen or alkyl (1-3C), Q is benzyl or 2-, 3- or 4-pyridylmethyl, wich groups may be substited with one or more more substituents from the group halogen, nitro, cyano, amino, mono- or di (1-3C)alkylamino, (1-3C) alkoxy, CF3, OCF3, SCF3, (1-4C)-alkyl, (1-3C)alkylsulfonyl or hydroxy,and salts and prodrugs thereof. It has been found that these compounds have interesting pharmacological properties due to a combination of (partial) agonism towards the members of the dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors.

4.

发明专利
Piperazinové a piperidinové slouceniny, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují 未知

公开(公告)号：CZ301464B6

公开(公告)日：2010-03-10

申请号：CZ20023721

申请日：2001-05-10

Applicant: SOLVAY PHARM BV

Inventor： FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , KRUSE CORNELIS G , LONG STEPHEN K , VAN SCHARRENBURG GUSTAAF J M

IPC: C07D413/04 , C07D413/10 , A61K31/423 , A61K31/428 , A61K31/4427 , A61K31/4439 , A61K31/445 , A61K31/4523 , A61K31/496 , A61P25/00 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/30 , A61P43/00 , C07D263/54 , C07D263/58 , C07D277/62 , C07D277/68 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14

Abstract: Slouceniny obecného vzorce I, jejich soli a profarmaka, zpusob prípravy techto sloucenin reakcí slouceniny obecného vzorce Ia se slouceninou Q-Hal, a farmaceutické kompozice obsahující tyto slouceniny. Tyto slouceniny vykazují zajímavé farmakologické vlastnosti díky kombinaci (cástecného) agonismu vuci clenum podrodiny dopaminových D.sub.2.n. receptoru a afinite k relevantním serotoninovým nebo/a noradrenergním receptorum. Proto lze tyto slouceniny použít k lécení príslušných onemocnení, zejména poruch centrální nervové soustavy, úzkosti, deprese, Parkinsonovy choroby a závislostí.

5.

发明专利
未知

公开(公告)号：AT255578T

公开(公告)日：2003-12-15

申请号：AT01938214

申请日：2001-05-10

Applicant: SOLVAY PHARM BV

Inventor： FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , KRUSE CORNELIS G , LONG STEPHEN K , VAN SCHARRENBURG GUSTAAF J M

IPC: C07D413/10 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/445 , A61K31/4523 , A61K31/496 , A61P25/00 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/30 , A61P43/00 , C07D263/54 , C07D263/58 , C07D277/62 , C07D413/04 , C07D413/12 , C07D413/14

6.

发明专利
USE OF COMPOUNDS HAVING COMBINED DOPAMINE D2, 5-HT1A AND ALPHA ADRENORECEPTOR AGONISTIC ACTION FOR TREATING CNS DISORDERS 未知

公开(公告)号：CA2405758A1

公开(公告)日：2001-11-15

申请号：CA2405758

申请日：2001-05-10

Applicant: SOLVAY PHARM BV

Inventor： VAN DER HEIJDEN JOHANNES A M , LONG STEPHEN K , FEENSTRA ROELOF W , VAN SCHARRENBURG GUSTAAF J M

IPC: C07D413/12 , A61K31/00 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K45/00 , A61K45/06 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P43/00

Abstract: The invention relates to the use of compounds having combined sopamine D2 agonistic activity, 5-HT1A agonistic activity and a adrenoceptor agonistic activity for the treatment of CNS disorders such as Parkinson's disease.

7.

发明专利
Piperazine and piperidine compounds, method for their preparation and pharmaceutical compositions comprising the same and their use 未知

公开(公告)号：SK286778B6

公开(公告)日：2009-05-07

申请号：SK15872002

申请日：2001-05-10

Applicant: SOLVAY PHARM BV

Inventor： FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , KRUSE CORNELIS G , LONG STEPHEN K , VAN SCHARRENBURG GUSTAAF J M

IPC: C07D413/00 , C07D413/10 , A61K31/00 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/445 , A61K31/4523 , A61K31/496 , A61P25/00 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/30 , A61P43/00 , C07D263/00 , C07D263/54 , C07D263/58 , C07D277/62 , C07D413/04 , C07D413/12 , C07D413/14

Abstract: Compounds of the formula (I) wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, ---Z represents -C, = C or -N, R1 and R2 independently represent hydrogen or alkyl (1-3C), Q is benzyl or 2-, 3- or 4-pyridylmethyl, wich groups may be substited with one or more more substituents from the group halogen, nitro, cyano, amino, mono- or di (1-3C)alkylamino, (1-3C) alkoxy, CF3, OCF3, SCF3, (1-4C)-alkyl, (1-3C)alkylsulfonyl or hydroxy. It has been found that these compounds have interesting pharmacological properties due to a combination of (partial) agonism towards the members of the dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors.